文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

血流动力学监测保障的液体平衡中和与方案化标准治疗在需要连续性肾脏替代治疗的急性循环衰竭患者中的比较:GO NEUTRAL随机对照试验结果

Fluid balance neutralization secured by hemodynamic monitoring versus protocolized standard of care in patients with acute circulatory failure requiring continuous renal replacement therapy: results of the GO NEUTRAL randomized controlled trial.
PubMed 文献 · Intensive Care Med · 2024-10-17
一句话结论在需要血管升压药和CRRT的急性循环衰竭患者中,经功能血流动力学方案调整的净超滤策略(UFNET≥100 ml·h⁻¹)较标准治疗(UFNET≤25 ml·h⁻¹)在72小时实现更负的液体平衡。

GO NEUTRAL是一项随机、对照、开放标签、平行组、多中心、概念验证试验,纳入接受血管升压药、CRRT开始≤24小时且有心输出量监测的成人,1:1随机分为干预组(72小时内UFNET≥100 ml·h⁻¹,按功能血流动力学方案调整)和对照组(UFNET≤25 ml·h⁻¹)。主要终点为72小时累积液体平衡,在改良意向治疗人群(mITT,72小时存活且持续监测和CRRT者)中分析。mITT人群(干预21例、对照24例)中,干预组72小时液体平衡为-2650 [-4574; -309] ml,对照组为1841 [821; 5327] ml,差异4942 ml(95%CI 2736-6902),P<0.01。72小时血流动力学、氧合、HIRRT次数及90天死亡率两组间无统计学差异。

要点

  • 在接受血管升压药且CRRT开始≤24小时的急性循环衰竭成人中,按功能血流动力学方案调整的UFNET(≥100 ml·h⁻¹)较UFNET≤25 ml·h⁻¹显著降低72小时累积液体平衡:干预组-2650 [-4574; -309] ml vs 对照组1841 [821; 5327] ml,差异4942 ml(95%CI 2736-6902),P<0.01。
  • 该主要结果基于mITT人群(72小时存活且持续监测和CRRT者),干预组21例、对照组24例。
  • 72小时血流动力学、氧合及HIRRT发生次数在两组间无统计学差异。
  • 90天死亡率在两组间无统计学差异。
  • 研究共随机55例(干预25例、对照30例),中位年龄69岁(IQR 62;74),女性35%,SOFA评分13(IQR 11;15)。

适用人群与场景

  • 成人患者,接受血管升压药,CRRT开始≤24小时,且具备心输出量监测。
  • 随机分组后72小时内接受干预或对照方案;主要分析人群为mITT(72小时存活且持续监测和CRRT者)。

处置流程与药物剂量

  • 干预组:72小时内UFNET≥100 ml·h⁻¹,按功能血流动力学方案调整。
  • 对照组:UFNET≤25 ml·h⁻¹。

研究设计与关键结果

  • 研究类型:随机、对照、开放标签、平行组、多中心、概念验证试验;2021年6月至2023年4月共随机55例(干预25例、对照30例)。
  • 人群特征:年龄69岁(IQR 62;74),女性35%,SOFA评分13(IQR 11;15)。
  • 主要终点(mITT人群,干预21例、对照24例):72小时累积液体平衡干预组-2650 [-4574; -309] ml vs 对照组1841 [821; 5327] ml,差异4942 ml(95%CI 2736-6902),P<0.01。
  • 次要终点:72小时血流动力学、氧合及HIRRT次数两组间无统计学差异;90天死亡率两组间无统计学差异。

证据类型、等级与局限

  • 证据类型:随机对照试验(概念验证试验)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在接受血管升压药的患者中,经血流动力学方案保障的UFNET液体清除策略较标准治疗能够实现积极的液体平衡控制。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Net ultrafiltration (UFNET) during continuous renal replacement therapy (CRRT) can control fluid balance (FB), but is usually 0 ml·h-1 in patients with vasopressors due to the risk of hemodynamic instability associated with CRRT (HIRRT). We evaluated a UFNET strategy adjusted by functional hemodynamics to control the FB of patients with vasopressors, compared to the standard of care.

METHODS: In this randomized, controlled, open-label, parallel-group, multicenter, proof-of-concept trial, adults receiving vasopressors, CRRT since ≤ 24 h and cardiac output monitoring were randomized (ratio 1:1) to receive during 72 h a UFNET ≥ 100 ml·h-1, adjusted using a functional hemodynamic protocol (intervention), or a UFNET ≤ 25 ml·h-1 (control). The primary outcome was the cumulative FB at 72 h and was analyzed in patients alive at 72 h and in whom monitoring and CRRT were continuously provided (modified intention-to-treat population [mITT]). Secondary outcomes were analyzed in the intention-to-treat (ITT) population.

RESULTS: Between June 2021 and April 2023, 55 patients (age 69 [interquartile range, IQR: 62; 74], 35% female, Sequential Organ Failure Assessment (SOFA) 13 [11; 15]) were randomized (25 interventions, 30 controls). In the mITT population, (21 interventions, 24 controls), the 72 h FB was -2650 [-4574; -309] ml in the intervention arm, and 1841 [821; 5327] ml in controls (difference: 4942 [95% confidence interval: 2736-6902] ml, P < 0.01). Hemodynamics, oxygenation and the number of HIRRT at 72 h, and day-90 mortality did not statistically differ between arms.

CONCLUSION: In patients with vasopressors, a UFNET fluid removal strategy secured by a hemodynamic protocol allowed active fluid balance control, compared to the standard of care.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Bitker L, Dupuis C, Pradat P, et al. Fluid balance neutralization secured by hemodynamic monitoring versus protocolized standard of care in patients with acute circulatory failure requiring continuous renal replacement therapy: results of the GO NEUTRAL randomized controlled trial. Intensive Care Med. 2024. PMID: 39417870. doi:10.1007/s00134-024-07676-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。